



Financial Tear Sheet

Corporate Profile

Global Blood Therapeutics, Inc. (GBT) is a clinical-stage biopharmaceutical dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its lead product candidate, GBT440, for the treatment of sickle cell disease and idiopathic pulmonary fibrosis.

Primary IR Contact

Myesha Lacy

Phone: 650-351-4730

E-mail: investor@gbt.com

Stock Performance

GBT (Common Stock)

Exchange NASDAQ GS (US Dollar)

Price **\$62.85**

Change (%) ▲ 0.20 (0.32%)

Volume 538,143

52 Week Low \$24.03

Market Cap \$2,891,564,650

Rolling EPS -2.55

PE Ratio 0

Shares Outstanding 46,007,393

Data as of 02/23/18 4:00 p.m. ET



Recent Headlines & Events

02/07/18

[GBT Announces Participation at the Leerink Partners
7th Annual Global Healthcare Conference](#)

01/09/18

[GBT Receives FDA Breakthrough Therapy Designation
for Voxelotor for Treatment of Sickle Cell Disease
\(SCD\)](#)

01/03/18

[GBT to Present at the 36th Annual J.P. Morgan
Healthcare Conference](#)

There are currently no events scheduled.

SEC Filings

Filing Date	Form
02/21/18	<u>4</u>
02/16/18	<u>4</u>
02/16/18	<u>4</u>
02/16/18	<u>4</u>

Corporate Governance

[Ted W. Love, M.D.](#) Chief Executive Officer

[Jeffrey Farrow](#) Chief Financial Officer

[Jung E. Choi](#) Chief Business and Strategy Officer

[Tricia Suvari](#) Chief Legal Officer

[Hing Sham, Ph.D.](#) Senior Vice President, Research

[Peter Radovich](#) Vice President, Program Leadership
and Business Strategy

Data provided by Nasdaq. Minimum 15 minutes delayed.